ProfileGDS5678 / 1427278_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 55% 60% 56% 52% 56% 59% 54% 55% 56% 56% 54% 56% 55% 56% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.4127755
GSM967853U87-EV human glioblastoma xenograft - Control 23.6064360
GSM967854U87-EV human glioblastoma xenograft - Control 33.4028256
GSM967855U87-EV human glioblastoma xenograft - Control 43.2140952
GSM967856U87-EV human glioblastoma xenograft - Control 53.3584956
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6242459
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.431854
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.3775855
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3779156
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3876756
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.3440654
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3801856
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3949955
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3909356